N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

Sponsor: Flare Therapeutics Inc. • ClinicalTrials.gov ID: NCT07719361

Registry updated: 2026-09-24
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are: What are the side effects of FX-111? Does FX-111 work to reduce or prevent progression of mCRPC? The study doctor will oversee participants' treatment with FX-111 and ask about any side effects. Participants will take FX-111 every day by mouth and will have regular physical and laboratory examinations to check health and tumor status.

Interventions

  • FX-111 (Drug)
    FX-111 will be administered orally once daily in continuous 28-day cycles.

Eligibility criteria

Inclusion Criteria: * Confirmed adenocarcinoma of the prostate. * PSA levels ≥ 2 ng/mL at screening visit. * Progressing PSA, defined as two consecutive increases in the most recent PSA measurements taken at least 1 week apart. * Progressed on Androgen Deprivation Therapy (ADT) and at least one prior potent Androgen Receptor (AR) pathway inhibitor given in castration-sensitive prostate cancer setting or approved for castration-resistant prostate cancer (eg, apalutamide, darolutamide, abiraterone, enzalutamide). * Ongoing primary ADT with gonadotropin-releasing hormone agonist or antagonist in the absence of bilateral orchiectomy. * Acceptable physical functioning and laboratory measurements, per the study protocol. * Discontinued prior therapies within protocol-specified timeframes. * Commit to use of highly-effective contraception while on study and for 90 days after. * Willing and able to adhere to the study visit schedule and other protocol defined requirements. Exclusion Criteria: * Predominance of small cell carcinoma of the prostate/neuroendocrine prostate cancer in most recent tumor biopsy. * Participants with brain metastases that require ongoing treatment with radiation or high-dose steroids. * Not recovered from side effects of prior surgery or cancer treatments. * Evidence of active viral, bacterial, or fungal infection requiring treatment with antivirals, antibiotics, or anti-fungal medications. * Prior treatment with AR degraders and molecules with an AR ligand such as AR Regulated Induced Proximity Targeting Chimera (RIPTAC). * Blood clots ≤ 4 weeks prior to start of treatment. * Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study drug. Patients may be eligible if the malignancy is clinically stable or has been treated with curative intent. * Any evidence of severe or uncontrolled systemic diseases. * Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of the patient's safety or study results.

Conditions

Metastatic Castration Resistant Prostate Cancer mCRPC mCRPC (Metastatic Castration-resistant Prostate Cancer) Prostatic Neoplasms Prostatic Neoplasms, Castration-Resistant mCRPC or Advanced/Metastatic Solid Tumors mCRPC, Metastatic Castration Resistant Prostate Cancer Neoplasms Prostate Neoplasms of Prostate

Locations

  • START Los Angeles — Los Angeles, California, United States
  • Massachusetts General Hospital — Boston, Massachusetts, United States
  • Dana Farber Cancer Institute — Boston, Massachusetts, United States
  • START Midwest — Grand Rapids, Michigan, United States
  • START New Jersey — East Brunswick, New Jersey, United States
  • START Carolinas — Myrtle Beach, South Carolina, United States
  • Tennessee Oncology — Nashville, Tennessee, United States
  • START Dallas-Fort Worth — Fort Worth, Texas, United States
  • NEXT Houston — Houston, Texas, United States
  • NEXT Oncology — San Antonio, Texas, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record